Overview

Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is to determine an effective dosage and to study the safety of an investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression of diabetic peripheral neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
The Institute for Diabetes Discovery, LLC